Article Text

Download PDFPDF
Review: cholinesterase inhibitors may be effective in Alzheimer’s disease

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with Alzheimer’s disease (AD), does treatment with cholinesterase inhibitors (donepezil, rivastigmine, or galantamine) improve clinical outcomes?

Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★★☆ Geriatrics ★★★★★★★ Psychiatry ★★★★★★☆ Neurology ★★★★★★☆


Embedded ImageData sources:

Medline (1989 to November 2004), EMBASE/Excerpta Medica (1989 to November 2004), the Cochrane Database of Systematic Reviews, and bibliographies of relevant studies.

Embedded ImageStudy selection and assessment:

randomised controlled trials (RCTs) (published in any language) that compared cholinesterase inhibitors (donepezil, rivastigmine, or galantamine) with placebo in patients with AD. Studies that did not examine clinical outcomes or focused on vascular dementia were excluded.

Embedded ImageOutcomes:

measures of clinical outcome included Alzheimer’s Disease Assessment-Cognitive Subscale, Clinician’s Interview-Based Impression …

View Full Text


  • For correspondence: Dr H Kaduszkiewicz, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. kaduszki{at}

  • Source of funding: not stated.